Introduction
Arsenic-contaminated drinking water is a common global health problem for millions of people (IARC 2012) . Arsenic is carcinogenic in humans with target tissues including the skin, lung, and urinary bladder and potentially the prostate, liver, and kidney (NTP 2011; IARC 2012) . Inorganic arsenic (iAs) and its methylated metabolite methylarsonous acid (MMA III ) both have carcinogenic potential in rodents (Waalkes et al. 2007; Tokar et al. 2010a Tokar et al. , 2012 IARC 2012) . Exposure to iAs also induces malignant transformation in vitro in skin, lung, liver, prostate, or kidney Abstract Inorganic arsenic (iAs) and its toxic methylated metabolite, methylarsonous acid (MMA III ), both have carcinogenic potential. Prior study shows iAs-induced malignant transformation in both arsenic methylation-proficient (liver) and methylation-deficient (prostate) cells, but only methylation-proficient cells show oxidative DNA damage (ODD) during this transformation. To further define whether arsenic methylation is necessary for transformation or ODD induction, here we chronically exposed these same liver or prostate cell lines to MMA III (0.25-1.0 μM) and tested for acquired malignant phenotype. Various metrics of oncogenic transformation were periodically assessed along with ODD during chronic MMA III exposure. Methylation-deficient and methylation-proficient cells both acquired a cancer phenotype with MMA III exposure at about 20 weeks, based on increased matrix metalloproteinase secretion, colony formation, and invasion. In contrast, prior work showed iAs-induced transformation took longer in biomethylation-deficient cells (~30 weeks) than in biomethylation-proficient cells (~18 weeks). In the present study, MMA III caused similar peak ODD levels at similar concentrations and at similar exposure times (18-22 weeks) in both cell types. At the approximate peak of ODD production, both cell types showed similar alterations in arsenic and oxidative stress adaptation factors (i.e., ABCC1, ABCC2, . Thus, MMA III causes oncogenic transformation associated with ODD in methylation-deficient cells, indicating that further methylation is 1 3 cells (Zhao et al. 1997; Achanzar et al. 2002; Pi et al. 2008; Tokar et al. 2010b; Li et al. 2011; Stueckel et al. 2012) . In addition, studies show that MMA III can effectively cause malignant transformation in vitro in urinary bladder cell lines (Bredfeldt et al. 2006; Wnek et al. 2010) . Given its reactivity and toxicity compared with unmethylated arsenicals (Styblo et al. 2000) , MMA III is believed by some to possibly be an important carcinogenic species. However, the exact carcinogenic species and mechanisms of arsenic carcinogenesis are not fully defined and likely are multifactorial (IARC 2012) .
Multiple endogenous and exogenous factors can stimulate the generation of reactive oxygen species (ROS) in mammalian cells. Oxidative stress and oxidative DNA damage (ODD) likely results once the buildup of ROS overwhelms cellular chemical defense mechanisms, including cellular antioxidants, enzymatic oxidant systems, and DNA repair mechanisms (Valko et al. 2006; Klaunig et al. 2011; Kryston et al. 2011) . This imbalance between cellular antioxidant repair systems and ODD can potentially lead to cancer due to accumulation of genetic mutations that can activate oncogenes and/or inactivate tumor suppressor genes (Valko et al. 2006; Klaunig et al. 2011; Kryston et al. 2011) . ROS generated during arsenic exposure or arsenic metabolism is suspected to play a role in arsenic-induced carcinogenesis (Valko et al. 2006; Kitchin and Conolly 2010) , although this has not been directly shown in tumor endpoint studies. However, studies have shown exposure to iAs or MMA III will induce ODD as a result of ROS generation (Nesnow et al. 2002; Gomez et al. 2006; Kojima et al. 2009; Wnek et al. 2011) . At least in some cells, this has been shown to be related to oncogenic transformation, as a blockade of arsenicalinduced ODD effectively blocks acquisition of cancer phenotype (Kojima et al. 2009 ).
Arsenicals can have various effects on the expression and/or function of DNA damage/repair mechanisms and pathways. For instance, phosphatase and tensin homologue (PTEN) is a tumor suppressor gene that is commonly mutated or deleted in cancers, but plays vital roles in proper DNA repair and DNA damage response pathways (Ming and He 2012) . Chronic exposure to arsenic depletes the expression of PTEN during cancer formation in vivo and during malignant transformation in vitro (Cui et al. 2004; Tokar et al. 2010a; Sun et al. 2012 ). Thus, not only can exposure to arsenicals induce ROS-mediated ODD (Nesnow et al. 2002; Gomez et al. 2006; Kojima et al. 2009; Wnek et al. 2011 ), but it can also inactivate various factors involved in DNA repair, thereby perturbing the repair process (Cui et al. 2004; Tokar et al. 2010a; Wnek et al. 2011; Sun et al. 2012) . These different roles in DNA damage and DNA repair may actually work in combination to facilitate the arsenic-induced oncogenic process. Indeed, arsenic-transformed skin keratinocytes are predisposed to UV-induced ODD but, because of prior adaptation to arsenic, are better able to survive a UV exposure insult that kills normal cells, allowing UV-damaged cells to bypass normal cell population checkpoints even though damaged (Sun et al. 2011) .
We have previously shown that chronic exposure to iAs induces malignant transformation in both iAs methylation-proficient (i.e., liver; Zhao et al. 1997 ) and methylation-deficient cells (i.e., prostate; Achanzar et al. 2002) . However, iAs exposure induces a much more rapid transformation concurrently with ODD in the methylation-proficient cells (Kojima et al. 2009 ). In methylation-deficient cells, iAs will induce malignant transformation (Achanzar et al. 2002) , but this occurs in the absence of any evidence of ODD and takes ~60 % longer than for methylation-proficient cells (29 vs. 18 weeks; Kojima et al. 2009 ). This suggests that either a methylated arsenical, such as MMA III , may be required for induction of ODD or the act of methylation itself may generate radicals. To directly test these possibilities, the present study exposed the same arsenic methylation-proficient liver cells (TRL1215) and methylation-deficient prostate cells (RWPE-1) to MMA III for up to 30 weeks. The cell lines were periodically assessed for ODD and acquisition of cancer cell characteristics during this exposure. In addition, several DNA oxidative stress response factors were measured in both cell types during MMA III exposure. Together with our previous study (Kojima et al. 2009 ), the current results show that for ODDassociated transformation, a methylated arsenic species is required, but further methylation is not necessary. ODDassociated arsenical-induced transformation appears more rapid as well. However, neither DNA damage nor arsenical methylation is required for arsenic-induced malignant transformation to occur in a given cell type.
Materials and methods

Chemicals and reagents
Sodium arsenite and p-iodonitrotetrazolium chloride (INT) were obtained from Sigma-Aldrich (St. Louis, MO). 5,5-dimethyl 1-pyrroline N-oxide (DMPO) was obtained from Alexis Biochemicals (San Diego, CA). MMA III was a kind gift from Dr. William R. Cullen, University of British Columbia.
Cells and cell culture RWPE-1 cell line is arsenic methylation incompetent (Benbrahim-Tallaa et al. 2005) and was cultured in complete keratinocyte serum-free medium (KSFM; Gibco/ Invitrogen, Carlsbad, CA) with epidermal growth factor (EGF) and bovine pituitary extract (BPE) supplements and 1 % antibiotic-antimicotic (Gibco/Invitrogen). The TRL1215 cell is arsenic methylation proficient (Zhao et al. 1997; Romach et al. 2000) and was cultured in William's E medium (Gibco/Invitrogen), containing 10 % fetal bovine serum (Gibco/Invitrogen), 31 μg/mL penicillin, and 50 μg/mL streptomycin. Both cell lines were cultured in a humidified atmosphere at 5 % CO 2 and 37 °C and chronically exposed to 0.0 (control), 0.25, 0.5, or 1.0 μM methylarsonous acid (MMA III ) for up to 30 weeks. Medium was changed twice/week, and sub-confluent cells were passaged weekly. The concentrations of MMA III used showed no effects on cell growth.
DNA isolation and measurement of ODD Isolation of DNA and measurement of ODD using the IST method were carried out as described in detail previously (Ramirez et al. 2006 (Ramirez et al. , 2007 Kojima et al. 2009 ). The IST method directly measures the formation of DNA-centered radicals by formation of adducts with DMPO, conversion to stable nitrone adducts, and subsequent immunochemical quantification. Measurements represent the mean of nine samples from three independent experiments.
Zymographic analysis for secreted MMP activity Secreted MMP-2 and MMP-9 as combined activity levels were measured using SDS-PAGE zymography as described (Tokar and Webber 2005) with one minor change for TRl1215 cells. MMA III in the medium of TRL1215 cells appeared to block activity of the MMPs in the conditioned medium. Trivalent arsenicals can inhibit various cellular enzymes (see Jomova and Valko 2011) . Therefore, to obtain an accurate measurement of MMP activity in TRL1215 cells, MMA III was removed from culture medium for 7 days before the collection of conditioned medium. MMPs from RWPE-1 cells were not similarly impacted. The difference may be that one group of MMP enzymes is from human cells (RWPE-1) and one is from rodent (TRL1215). For MMP assessment, 5 μg of protein/well from conditioned media was loaded (n = 3). Gels were electrophoresed at 160 V for 1.5 h and incubated in renaturing buffer at room temperature (two separate washes, 30 min each), followed by incubation in developing buffer at room temperature (30 min) and then developing buffer at 37 °C for 18-20 h. Gels were then soaked in SimplyBlue Safestain (Invitrogen) for approximately 4 h. Clear bands, indicating MMP activity, were measured by ImageJ software (NIH). Three independent samples (n = 3) were loaded for each treatment, and measurements for controls were set at 100 %.
Agar assay
The ability of MMA III -treated cells to grow in an anchorage-independent manner, a common characteristic of cancer cells, was examined using a soft agar assay as described (Tokar and Webber 2005) . Colonies were allowed to form over 21 days and counted with an automated colony counter. Triplicate dishes were prepared for control and treated cells and counts for control were set at 100 %.
Invasion assay
As another indicator of in vitro transformation, cellular invasiveness was examined using a modified Boyden chamber assay as described (Tokar and Webber 2005) . Cells that had invaded into and through the membrane and into the bottom chamber were counted. Untreated cells were used as the control and set as 100 % for quantitation of results. Triplicate samples of each group were assessed.
Real-time reverse transcription polymerase chain reaction
Total RNA was collected from sub-confluent cells using TRIzol reagent (Invitrogen), purified with Rneasy mini kit columns (Qiagen, Valencia, CA), and transcribed with MuLV reverse transcriptase and oligo-DT primers. Primers were designed using Primer Express 3.0 software (Applied Biosystems). Amplifications were done using the Absolute SYBR Green ROX Mix (Abgene, Rockford, IL). Cycle time (Ct) values were normalized to those of β-actin and glyceraldehyde-3-phosphate dehydrogenase in the same sample. Three independent flasks (n = 3) for each treatment were collected, and Ct values for control cells were set at 100 %.
Results
MMA
III induces similar oncogenic characteristics regardless of methylation capacity Increased secretion of active matrix metalloproteinases (MMPs) is a common occurrence in cancer cells, which aids invasion and metastasis. Activity of secreted MMPs was measured in MMA III -exposed cells. Both cell lines showed time-dependent increases in secreted MMP activity during chronic MMA III exposure (Fig. 1) . By 20 weeks or more of exposure, these levels (2.1-4.5-fold of control) were equal to or exceeded those typically seen in cells that produce xenograft tumors when transformed in vitro with arsenicals (Achanzar et al. 2002; Pi et al. 2008; Kojima et al. 2009; Tokar et al. 2010c; Huang et al. 2011; Sun et al. 2012) . Colony formation in soft agar measures the 1 3 ability of cells to grow in an anchorage-independent manner, a common characteristic of cancer cells. Liver cells started showing an increase in colony formation starting at 5 weeks of MMA III exposure, which generally increased thereafter (Fig. 2a) . Starting at 15 weeks of MMA III exposure, the prostate cells started showing a time-dependent increase in colony formation (Fig. 2b) . Further methylation of MMA III may help explain the earlier increase in colony formation in TRL1215 cells. This observation requires further study with MMA III with an inhibitor of methylation or further methylation to a metabolite such as dimethylarsinous acid (DMA III ). The prostate and liver cells also showed very similar increases in invasive ability, following exposure to MMA III . Starting at 15 weeks of exposure, both cell lines started showing significant, time-dependent increases in invasive ability to maximal increases of 4.8-fold (TRL1215) and 4.6-fold (RWPE-1) by 30 weeks of exposure (Fig. 2c, d ).
III exposure and decreased PTEN PTEN is a tumor suppressor gene commonly decreased in cancer cells, including arsenic-induced tumor cells. PTEN is also known to play a key role in DNA damage and repair. MMA III exposure caused comparable, sustained decreases in PTEN transcript levels starting at 10 weeks in methylation-deficient RWPE-1 cells and methylation-proficient TRL1215 cells (Fig. 3) .
In total, the increased MMP secretion, colony formation, and invasion as well as the loss of PTEN expression between 20 and 25 weeks were similar to or exceeded values for cells that have been shown to have tumor-forming capacity in xenograft studies (Achanzar et al. 2002; Pi et al. 2008; Kojima et al. 2009; Tokar et al. 2010c; Wnek et al. 2010; Huang et al. 2011 ).
MMA III induces ODD independent of ability to methylate arsenic
The methylation-deficient prostate and the methylationproficient liver cell lines showed a strikingly similar ODD pattern during MMA III exposure at the highest concentration of exposure (1.0 μM; Fig. 4 ). Both cell lines showed a delayed (2-4 weeks) pattern of increased ODD and surprisingly comparable maximal increases between 18 weeks (RWPE-1, 416 %) and 22 weeks (TRL1215, 466 %) at the highest (1 μM) concentration of MMA III used. Both cell lines then showed a precipitous decrease in ODD back to control levels by 30 weeks of exposure (Fig. 4) . This pattern of ODD induction occurred in a concentration-dependent manner in both cell lines (Fig. 4) .
Direct comparison of concentration-response for ODD at the peak of activity (at around 20 weeks from data in Fig. 4 ) for the two cell lines proved interesting (Fig. 5) . At the highest MMA III concentration used (1 μM), the peak ODD levels were very similar between the two cell lines. The ODD levels at the two lower concentrations (0.25 and 0.5 μM) tended to be somewhat lower in the methylating liver cells (30-33 % less) than in the non-methylating prostate cells, perhaps indicating that further methylation may produce a metabolite less prone to cause ODD than MMA III and this capacity is not saturated at lower concentrations.
In comparing the present results with MMA III in methylation-proficient and methylation-deficient cells to earlier work with iAs transformation and ODD generation in these (Kojima et al. 2009 ), several important conclusions become apparent. Firstly, liver (TRL1215) cells that can methylate iAs were transformed at a similar time point with either iAs or MMA III treatment but showed much more MMP secretion and peak levels of ODD at the approximate point of transformation with iAs exposure (Kojima et al. 2009 ; Fig. 6a, b) . Thus, the formation of MMA III from iAs seems to enhance ODD and cellular aggressiveness. In sharp contrast, methylation-deficient prostate (RWPE-1) cells showed no ODD over baseline with iAs treatment and it took ~30 weeks for them to undergo transformation compared to only 20 weeks to transform these cells with
MMA
III along with marked increases in ODD (Fig. 6c, d ). These distinctions likely have mechanistic significance.
Effects of MMA
III on arsenic adaptation-and stress-related factors
Various genes that can become altered in an adaptive response to chronic arsenical exposure or other types of stress were examined during chronic MMA III exposure. For genes associated with arsenical efflux, in prostate cells, transcript levels of ABCC1 were initially decreased (10 weeks) but increased to levels above control at 20 and 30 weeks, while levels of ABCC2 and GST-π were increased at 20 and 30 weeks (Fig. 7) . Transcript levels of all these genes in liver cells were increased at 10, 20, and 30 weeks except for GST-π, which was increased only at 20 and 30 weeks (Fig. 7) . For genes associated with response to oxidant stress, MMA III exposure caused cell line-specific opposing effects on heme oxygenase-1 (HO-1) between the cell lines, increasing transcript in prostate cells and decreasing it in liver cells (Fig. 8) . SOD-1 transcript levels increased in both cell lines at 20 and 30 weeks, while SOD-2 decreased in prostate cells and showed a decrease only at 10 weeks in liver cells (Fig. 8) . NRF2 showed an early decrease at 10 weeks but returned to control levels by 20 weeks in prostate cells (Fig. 8 ) but showed no change in liver cells during MMA III exposure (Fig. 8) .
Discussion
Arsenic is one of the earth's most widespread natural environmental toxicants and a known human carcinogen (NTP 2011; IARC 2012) , making exposure to this metalloid a considerable worldwide health problem. The exact carcinogenic arsenic species and mechanisms of oncogenesis are not fully defined. Based on our previous study using only iAs exposure in vitro and arsenic methylation-proficient and methylation-deficient cell lines (Kojima et al. 2009 ), we hypothesized that a methylated metabolite like MMA III could be able to induce ODD and cause acquisition of a cancer phenotype independent of the arsenic biomethylation ability of the cells. Other work has linked MMA III to cellular DNA damage (Mass et al. 2001; Schwerdtle et al. 2003) in vitro but has not linked this event to acquisition of cancer phenotype. To test this hypothesis, the present study chronically exposed the arsenic methylation-deficient prostate (RWPE-1) cells and the methylation-proficient liver (TRL1215) cells to MMA III for up to 30 weeks and examined ODD induction and acquired cancer phenotype. We found that both methylation-proficient and methylation-deficient cells acquired cancer cell characteristics concurrently with ODD during chronic MMA III exposure. These findings, combined with prior work (Kojima et al. 2009 ), lead to several important conclusions. One is that arsenic methylation is not required for arsenical-induced ODD, as it occurs with MMA III in methylation-deficient cells without further methylation. Secondly, both MMA III and iAs can induce a malignant phenotype in a methylation-deficient, target-relevant cell, but MMA III does so more rapidly and with concurrent ODD (see Fig. 6 ). This indicates that iAs, with methylation, likely can have both genotoxic and non-genotoxic effects when causing cell transformation, extending and further supporting similar conclusions in earlier work (Kojima et al. 2009 ). Furthermore, it appears that iAs, with subsequent methylation, greatly enhances ODD, as seen by comparing earlier data from methylation-proficient liver cells exposed to iAs (Kojima et al. 2009 ) to those from methylation-proficient cells exposed to MMA III exposure in this study (see Fig. 6 ). This could be important in target cells of arsenic carcinogenesis that do not methylate but may be exposed to methylated compounds generated elsewhere, such as the uroepithelium.
During the multi-step process of carcinogenesis, cells acquire several biological characteristics that allow them to become cancerous by circumventing the constraints of a "normal" phenotype (Hanahan and Weinberg 2011; Floor et al. 2012) . In the present study, both cell lines showed increases in several of these characteristics to levels at or above cells that were malignantly transformed by chronic iAs exposure as established by cellular behavior (invasion, colony formation, MMP secretion, and xenograft formation; Achanzar et al. 2002; Pi et al. 2008; Tokar et al. 2010a; Sun et al. 2012) . In this regard, MMPs play many important roles during carcinogenesis and are usually elevated in cancer cells compared to their normal counterparts (Kessenbrock et al. 2010) . Invasion into neighboring tissues and metastasis to distant sites are two defining and classical properties of malignant cells (Hanahan and Weinberg, 2011) . The ability of cells to grow in an anchorage-independent manner and form colonies in soft agar is commonly used to measure in vitro cancer phenotype and is positively correlated with in vivo tumorigenicity (Leone et al. 1991) . The time-dependent increases seen in these transformation markers strongly suggest that MMA III exposure induced an acquired cancer phenotype in both the arsenic methylating cells (TRL1215) and the non-methylating cells (RWPE-1). Moreover, the similarities in the increases in cancer cell characteristics between the cell lines suggest that MMA III -induced transformation occurs at a similar time (~20 weeks) and to a generally similar degree of aggressiveness. This is in sharp contrast to a comparison of MMA III -induced transformation with iAs-induced transformation in these same cell lines. The methylation-proficient liver cells showed markedly different increases in the various transformation markers and ODD during exposure to iAs, which were much higher than during transformation with MMA III (see Fig. 6 ; Kojima et al. 2009 ). MMP secretion and ODD were several folds higher at the approximate point of transformation in the methylation-proficient liver cells treated with iAs compared with MMA III (Kojima et al. 2009 ). This again indicates the first step in inorganic arsenic methylation as important in the generation of ODD. In contrast, transformation of methylation-deficient RWPE-1 cells not only appeared to take longer with iAs (~30 weeks; Kojima et al. 2009 ) than with MMA III (present study), but the levels of increased colony formation and MMP secretion were much higher with MMA III transformation than with iAs in these cells (present study; Kojima et al. 2009) . So it appears that when the non-methylating cells were transformed with an arsenical that causes ODD, it clearly does so more rapidly and creates a more aggressive transformant.
PTEN is one of the most commonly mutated genes in human and rodent cancers and plays critical roles in the pathogenesis of this disease (Di Cristofano and Pandolfi 2000) . Further evidence of an acquired cancer phenotype in both cell lines during chronic MMA III exposure is the loss of expression of the PTEN tumor suppressor gene. Recent evidence shows that PTEN is also vital for proper DNA damage repair and DNA damage response (Ming and He 2012) , and therefore, its loss or depletion could increase the chance of genomic instability (Kryston et al. 2011) . Thus, the loss of this protective factor could help explain the induction of ODD seen in this study. Moreover, this MMA III -induced depletion of PTEN expression is consistent with that seen during malignant transformation and tumor formation by other arsenicals (Cui et al. 2004; Tokar et al. 2010a; Sun et al. 2012) , suggesting a common mechanism in several models of arsenical-induced carcinogenesis. Previous studies have shown that arsenicals (iAs, MMA III ) can alter signaling via Akt phosphorylation, but these exposures had no effect on PTEN levels (Paul et al. 2007) . Whether the MMA III -induced PTEN depletion in the present study translates into altered signaling via increased Akt signaling requires further study.
Increased generation of reactive oxygen species (ROS) can overwhelm cellular defense mechanisms and eventually lead to oxidative stress and ODD. ODD plays a critical role in carcinogenesis and frequently results in mutagenesis and transformation (Valko et al. 2006; Klaunig et al. 2011; Kryston et al. 2011 ). In addition, generation of ODD is often times reliable evidence of oxidative stress in malignantly transformed cells (Kryston et al. 2011) . In this regard, ROS-generated oxidative stress and mutation is believed to be an important mechanism in arsenicinduced cancers (Valko et al. 2006; Kitchin and Conolly 2010) as exposure to arsenicals induces ODD in various cells (Nesnow et al. 2002; Gomez et al. 2006; Kojima et al. 2009; Wnek et al. 2011) . In the present study, MMA III caused a remarkably similar temporal pattern of ODD generation in both methylation-deficient cells and methylationproficient cells. Exposure of these same two cell lines to iAs induced ODD only in the methylation-proficient cell line, although both cell lines could be malignantly transformed by the metalloid (Kojima et al. 2009 ). Together, these results suggest that a methylated arsenical, such as MMA III , is obligatory for the generation of ODD though it may not be necessary for malignant transformation with iAs. This is an important point because it appears that various target cells of arsenic carcinogenesis only poorly methylate iAs, including human prostate epithelial, keratinocytes, bronchial, and bladder epithelial cells (Styblo et al. 2000; Benbrahim-Tallaa et al. 2005) . Additionally, further methylation to a dimethylated metabolite appears not necessary for malignant transformation, at least in the methylation-deficient cell line used in this study.
Several arsenic adaptation-and antioxidant-related factors that likely play a role in arsenic tolerance and perhaps Peak ODD levels at the highest MMA III concentration (1 μM) were similar between the two cell lines but at the lower concentrations (0.25 and 0.5 μM) tended to be somewhat lower in the methylation-proficient liver cells compared with the methylation-deficient prostate cells. Data were taken from Fig. 4 the current observed pattern of ODD generation were altered in both cell lines during MMA III -induced transformation. ABC transporter proteins (ABCC1, ABCC2) and GST-π work together to efflux arsenic and are associated with arsenic tolerance (Kala et al. 2000; Liu et al. 2001; Leslie et al. 2004) . These factors and others such as heme oxygenase-1 (HO-1), superoxide dismutases (SOD), and NRF2 play important roles in innate resistance and/or adaptation to arsenic by preventing arsenic-induced oxidative damage and apoptosis (Gottesman et al. 2002; Lee et al. 2003; Tokar et al. 2010c) . However, it must be kept in mind that such features allow for generalized resistance to apoptosis, and with this adaptation to arsenic toxicity, an expansion of a malignant phenotype can occur (McKenzie and Kyprianou 2006; Tokar et al. 2010c; Hanahan and Weinberg 2011) . During MMA III -induced transformation, there were similar expression trends of several adaptation/ oxidative stress factors in the cell lines. The lower levels of many of these factors (~10 weeks) may play a role in the induction or early increases in ODD. However, the increases in these factors at 20 and 30 weeks could lower ROS levels, which could, in turn, prevent ODD from occurring. The opposing trends of some factors (i.e., SOD-2, HO-1) between the cell lines suggest that different mechanisms may be at play during MMA III -induced transformation. These different mechanisms may be due to different Kojima et al. (2009) 1 3 methylation abilities or due to derivation of the cell lines from different species and/or different tissues. These results serve to point out how dynamic and varied the cellular response is to arsenical exposure.
ODD is predominantly linked to the initiation step of the multi-step process of carcinogenesis (Valko et al. 2006) . Genomic instability and mutation is considered an "enabling characteristic" that facilitates the acquisition of the hallmarks of cancer cells (Hanahan and Weinberg 2011) . Chronic arsenic exposure has recently been shown to induce the transformation of epithelial cells and decrease ROS generation in the transformed cells, which, in turn, enhanced cell growth and colony formation in the transformed cells (Chang et al. 2010) . Since ROS are pivotal in inducing apoptosis (Shimizu et al. 2004) , their reduction once cells are transformed could help explain the enhanced cell survival in cancer cells with reduced ROS levels (Sørlie et al. 2001; Chang et al. 2010 ). This could also lead to an enriched population of cells containing an increased resistance to ROS and to further induction of ROS. Reduced ROS level, partly due to an elevated level of ROS scavenging factors, is a key mechanism for resistance in normal stem cells and cancer stem cells in various tissues (Ito et al. 2004; Diehn et al. 2009 ). In this regard, arsenic-induced malignant transformation and tumor formation result in an overabundance of cancer stem cells (Waalkes Tokar et al. 2010a Tokar et al. , c, 2011 Sun et al. 2012; Xu et al. 2012) . Moreover, during arsenic-induced tumor formation and malignant transformation, cells show elevated levels of various oxidative stress factors, which helps the cells adapt to the metalloid (Liu et al. 2001; Pi et al. 2008; Tokar et al. 2010c; Sun et al. 2011) . All together, these elements could help explain the temporal pattern of ODD seen in both cell lines during MMA III -induced transformation. The early induction and increases in ODD could be acting as the "enabler" characteristic that is needed before the other cancer hallmarks (i.e., anchorage-independent growth, invasion) can occur. The subsequent drop in ODD appears to occur after all the cancer cell characteristics have reached significant levels that suggest that acquisition of a malignant phenotype has occurred. This drop may be the result of a reduction in induced ROS and a method by which cells avoid arsenic-induced toxicity and/or apoptosis and maintain long-term survival. It may also be the result of arsenic selecting and expanding a more stem-like population for transformation with a resultant enrichment of cancer stem cells, as has been seen in several other studies of chronic arsenic exposure Tokar et al. 2010a, c; Sun et al. 2012; Xu et al. 2012) . Defining the exact mechanisms involved in the observed temporal ODD pattern is beyond the scope of this present study. However, it is reasonable to suggest that some or all of these factors could be at play and, thus, warrant further investigation.
In summary, results from the present study, combined with our previous study (Kojima et al. 2009 ), demonstrate that arsenic methylation is not required for acquisition of a malignant phenotype. However, cellular ability to methylate arsenic may hasten and aggravate this transformation. Furthermore, the first methylation step of iAs appears to add significantly to ODD and burden as exposure of methylation-proficient cells to MMA III appears not to be as good a DNA oxidant as iAs. These findings may be particularly relevant given the different polymorphisms of As3MT, the main enzyme involved in arsenic methylation, and/or the variability in the activities of different reductants between human sub-populations Engström et al. 2011) . Nonetheless, taken together these results suggest that arsenicals can have both genotoxic and non-genotoxic mechanisms of action and also serve as a "complete carcinogen".
